APX3330

· Ocuphire Pharma, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for APX3330, covering 2023-02-27 to 2026-06-08. Get the full timeline:

Most recent: Clinical Trial Results: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy [Phase 2]